Table 6 Impact of GP88 and other clinical risk factors on overall survival.

HR

CI

P- value

P -value

HR

CI

Interaction P -value

GP88 (3+ vs. < 3+)

2.45

1.53 to 3.92

0.0005

0.0002

2.45

1.54 to 3.94

-

Ethnicity (Caucasian vs. non-Caucasian)

1.29

0.74 to 2.25

0.3821

0.0003

2.41

1.50 to 3.87

0.87

Tumor size (> 2 cm vs. ≤ 2 cm)

1.66

1.22 to 2.26

0.0024

0.0012

2.21

1.3 to 3.57

0.67

Tumor size (> 5 cm vs. ≤ 5 cm)

2.18

1.08 to 4.37

0.0479

Grade (> 1 vs. ≤ 1)

1.12

0.35 to 3.55

0.8441

0.0011

2.22

1.38 to 3.59

0.41

Grade (> 2 vs. ≤ 2)

2.11

1.30 to 3.43

0.0015

Stage (> 1 vs. ≤ 1)

3.65

1.88 to 7.06

0.0001

0.0075

1.93

1.19 to 3.12

0.48

Stage (> 2 vs. ≤ 2)

3.59

2.19 to 5.91

< .0001

Nodal status (Pos. vs. Neg.)

2.35

1.47 to 3.77

0.0002

0.0008

2.25

1.40 to 3.60

0.50

Age (> 50 yrs vs. ≤ 50 yrs)

1.83

1.06 to 3.15

0.0204

0.0002

2.44

1.53 to 3.90

0.37

PR (Pos. vs. Neg.)

0.92

0.55 to 1.55

0.7681

0.0001

2.71

1.63 to 4.51

0.62

Adjuvant endocrine therapy (Pos. vs. Neg.)

1.28

0.78 to 2.09

0.3205

0.0002

2.42

1.51 to 3.87

0.27

Adjuvant

chemotherapy (Pos vs. Neg.)

1.24

0.81 to 1.89

0.3255

0.0003

2.40

1.49 to 3.88

0.07

Adjuvant radiotherapy (Pos. vs. Neg.)

2.40

1.49 to 3.86

0.0008

0.007

2.00

1.21 to 3.30

0.45